A phase 1 ‘window-of-opportunity’ trial testing evofosfamide (TH-302), a tumour-selective hypoxia-activated cytotoxic prodrug, with preoperative chemoradiotherapy in oesophageal adenocarcinoma patients

BACKGROUND: Neo-adjuvant chemoradiotherapy followed by surgery is the standard treatment with curative intent for oesophageal cancer patients, with 5-year overall survival rates up to 50 %. However, patients’ quality of life is severely compromised by oesophagectomy, and eventually many patients die...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:BMC Cancer
Hauptverfasser: Larue, Ruben T. H. M., Van De Voorde, Lien, Berbée, Maaike, van Elmpt, Wouter J. C., Dubois, Ludwig J., Panth, Kranthi M., Peeters, Sarah G. J. A., Claessens, Ann, Schreurs, Wendy M. J., Nap, Marius, Warmerdam, Fabiënne A. R. M., Erdkamp, Frans L. G., Sosef, Meindert N., Lambin, Philippe
Format: Artigo
Sprache:Inglês
Veröffentlicht: BioMed Central 2016
Schlagworte:
Study Protocol
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC4989456/
https://ncbi.nlm.nih.gov/pubmed/27535748
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12885-016-2709-z
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge